Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Yun K. Hom"'
Autor:
W. Michael Korn, Andrew H. Ko, Yun K. Hom, Byron Hann, Peter M. Schaefer, Eric A. Collisson, Olga K. Mirzoeva
PDF - 2708K, Responses of a panel of 29 pancreatic cell lines to a combination of MEKi PD0325901 and EGFRi Erlotinib. Dose/effect curves for each inhibitor and their combinations at fixed molar ratio are presented. IC50 was calculated for each drug a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19f0a521e4c5b8fe3114de29334884b0
https://doi.org/10.1158/1535-7163.22498798
https://doi.org/10.1158/1535-7163.22498798
Autor:
W. Michael Korn, Andrew H. Ko, Yun K. Hom, Byron Hann, Peter M. Schaefer, Eric A. Collisson, Olga K. Mirzoeva
PDF - 1610K, List of Predictors.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60dd8467aecd85fee3070d2e589528a7
https://doi.org/10.1158/1535-7163.22498783
https://doi.org/10.1158/1535-7163.22498783
Autor:
W. Michael Korn, Andrew H. Ko, Yun K. Hom, Byron Hann, Peter M. Schaefer, Eric A. Collisson, Olga K. Mirzoeva
PDF - 47K, Legends for Supplementary Figures 1-3.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cc1b37b7b3e6d28bbd917193a7cf0b9
https://doi.org/10.1158/1535-7163.22498786.v1
https://doi.org/10.1158/1535-7163.22498786.v1
Autor:
W. Michael Korn, Andrew H. Ko, Yun K. Hom, Byron Hann, Peter M. Schaefer, Eric A. Collisson, Olga K. Mirzoeva
PDF - 968K, Western blot analysis of the biochemical response of two epithelial (HPAF-II and Panc10.05) and two mesenchymal (Panc2.13 and PA-TU8988T) PDAC cell lines treated with MEK inhibitor CI1040 in the presence or absence of ZEB1 knockdown.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9730fa3d82b6a6e682548e5130a77d3b
https://doi.org/10.1158/1535-7163.22498789.v1
https://doi.org/10.1158/1535-7163.22498789.v1
Autor:
W. Michael Korn, Andrew H. Ko, Yun K. Hom, Byron Hann, Peter M. Schaefer, Eric A. Collisson, Olga K. Mirzoeva
Mutations in the KRAS oncogene are dominant features in pancreatic ductal adenocarcinoma (PDA). Because KRAS itself is considered “undruggable,” targeting pathways downstream of KRAS are being explored as a rational therapeutic strategy. We inves
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ca6ed9b875519fc68f28ad036deec44
https://doi.org/10.1158/1535-7163.c.6535969
https://doi.org/10.1158/1535-7163.c.6535969
Autor:
Kevin C. Weng, Charles O. Noble, Brigitte Papahadjopoulos-Sternberg, Fanqing F. Chen, Daryl C. Drummond, Dmitri B. Kirpotin, Donghui Wang, Yun K. Hom, Byron Hann, John W. Park
Publikováno v:
Nano Letters; Aug2008, Vol. 8 Issue 9, p2851-2857, 7p
